CoChat
Sign Up
Cited by 32MicroRNA in disease regulationGlioma Diagnosis and TreatmentCancer-related molecular mechanisms research

Prognostic Significance of MicroRNAs in Glioma: A Systematic Review and Meta-Analysis

Open access
Zhang, Yanming, Chen, Jigang, Xue, Qiang, Wang, Junyu, Zhao, Liang, Han, Kaiwei, Zhang, Danfeng, Hou, Lijun·2019·BioMed Research International
DOI 10.1155/2019/4015969PMC PMC6457304
Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose. Different microRNAs (miRs) have been demonstrated to relate with the outcome of glioma patients, while the conclusions are inconsistent. We perform a meta-analysis to clarify the relationship between different miRs and prognosis of glioma.Methods. Related studies were retrieved from PubMed, Embase, and Cochrane Library. Pooled hazard ratios (HRs) of different miRs expression for survival and 95% confidence intervals (CIs) were calculated using random-effects model.Results. A total of 15 miRs with 4708 glioma patients were ultimately included. Increased expression of miR-15b (HR, 1.584; 95% CI, 1.199-2.092), 21 (HR, 1.591; 95% CI, 1.278-1.981), 148a (HR, 1.122; 95% CI, 1.023-1.231), 196 (HR, 1.877; 95% CI, 1.033-3.411), 210 (HR, 1.251; 95% CI, 1.010-1.550), and 221 (HR, 1.269; 95% CI, 1.054-1.527) or decreased expression of miR-106a (HR, 0.809; 95% CI, 0.655-0.998) and 124 (HR, 0.833; 95% CI, 0.729-0.952) was correlated with poor outcome of glioma patients.Conclusions. miR-15b, 21, 148a, 196, 210, 221, 106a, and 124 are valuable biomarkers for the prognosis of glioma which might be used in clinical settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2019/4015969

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A meta-analysis of nine studies revealed that high miR-21 expression is associated with a poor prognosis in glioma patients.

    “A meta-analysis of nine studies revealed that high miR-21 expression is associated with a poor prognosis in glioma patients [34], [35].”

    From miR-21 as a diagnostic and prognostic biomarker in glioma: tissue and serum expression analysis in a Pakistani cohort (2026) · cites this paper as [34]

    Results §3.4 reports that higher miR-21 expression significantly predicted poor prognosis in glioma patients. It says six studies examined miR-21, not nine. (LLM, conf=0.92)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. [1]Ferlay J. Shin H. R. Bray F. Forman D. Mathers C. Parkin D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 International Journal of Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 2-s2.0-78049485263 21351269 · DOI
  2. [2]Verhaak R. G. Kapurdom H. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010 17 1 98 110 10.1016/j.ccr.2009.12.020 2-s2.0-73649123907 20129251 PMC2818769 · DOI · Paper page
  3. [3]Schwartzbaum J. A. Fisher J. L. Aldape K. D. Wrensch M. Epidemiology and molecular pathology of glioma Nature Clinical Practice Neurology 2006 2 9 494 503 2-s2.0-33747790218 10.1038/ncpneuro0289 16932614 · DOI
  4. [4]Fan Z. Wu Y. Shen J. Zhan R. Glutathione S-transferase M1, T1, and P1 polymorphisms and risk of glioma: A meta-analysis Molecular Biology Reports 2013 40 2 1641 1650 2-s2.0-84878354240 10.1007/s11033-012-2213-8 23079710 · DOI
  5. [5]Nie S. Chen T. Yang X. Huai P. Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: A meta-analysis Diseases of the Esophagus 2014 27 7 645 653 2-s2.0-84906789897 10.1111/dote.12194 24635571 · DOI
  6. [6]Stupp R. Hegi M. E. Mason W. P. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial The Lancet Oncology 2009 10 5 459 466 10.1016/S1470-2045(09)70025-7 2-s2.0-65349121788 19269895 · DOI
  7. [7]Stupp R. Mason W. P. van den Bent M. J. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma Clinical Medicine Oncology 2005 2 10 421 422 10.1056/NEJMoa043330 2-s2.0-20044366163 PMC3161656 21892310 · DOI · Paper page
  8. [8]Winter J. Jung S. Keller S. Gregory R. I. Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation Nature Cell Biology 2009 11 3 228 234 10.1038/ncb0309-228 2-s2.0-61849137222 19255566 · DOI
  9. [9]Schwarzenbach H. Nishida N. Calin G. A. Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer Nature Reviews Clinical Oncology 2014 11 3 145 156 10.1038/nrclinonc.2014.5 24492836 · DOI
  10. [10]Yoshino H. Seki N. Itesako T. Chiyomaru T. Nakagawa M. Enokida H. Aberrant expression of microRNAs in bladder cancer Nature Reviews Urology 2013 10 7 396 404 10.1038/nrurol.2013.113 2-s2.0-84880253813 23712207 · DOI
  11. [12]Katada T. Ishiguro H. Kuwabara Y. MicroRNA expression profile in undifferentiated gastric cancer International Journal of Oncology 2009 34 2 537 542 10.3892/ijo_00000179 2-s2.0-64549124430 19148490 · DOI
  12. [13]Wang Y. Gao X. Wei F. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis Gene 2014 533 1 389 397 10.1016/j.gene.2013.09.038 24076132 · DOI
  13. [14]Wang L. Yu J. Xu J. Zheng C. Li X. Du J. The analysis of microRNA-34 family expression in human cancer studies comparing cancer tissues with corresponding pericarcinous tissues Gene 2015 554 1 1 8 10.1016/j.gene.2014.10.032 2-s2.0-84912122688 25452192 · DOI
  14. [15]Pang C. Guan Y. Zhao K. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma International Journal of Clinical and Experimental Pathology 2015 8 5 4943 4952 2-s2.0-84937797636 26191187 PMC4503059
  15. [16]Sun G. Yan S. Shi L. Decreased expression of miR-15b in human gliomas is associated with poor prognosis Cancer Biotherapy and Radiopharmaceuticals 2015 30 4 169 173 10.1089/cbr.2014.1757 25811315 PMC4426309 · DOI
  16. [18]Hermansen S. K. Dahlrot R. H. Nielsen B. S. Hansen S. Kristensen B. W. The tumor cell compartment holds the unfavorable prognostic value of miR-21 in gliomas Clinical Neuropathology 2014 31 6 p. 465 10.1158/1538-7445.AM2012-195 23104517 · DOI
  17. [19]Li X. Zheng J. Chen L. Diao H. Liu Y. Predictive and prognostic roles of abnormal expression of tissue miR-125b, miR-221, and miR-222 in glioma Molecular Neurobiology 2016 53 1 577 583 10.1007/s12035-014-9017-x 25502291 · DOI
  18. [20]Sun C. Zhao X. Joint covariate detection on expression profiles for selecting prognostic miRNAs in glioblastoma BioMed Research International 2017 2017 10 3017948 10.1155/2017/3017948 PMC5377059 28409153 · DOI
  19. [21]Stroup D. F. Berlin J. A. Morton S. C. Meta-analysis of observational studies in epidemiology: a proposal for reporting Journal of the American Medical Association 2000 283 15 2008 2012 10.1001/jama.283.15.2008 2-s2.0-0034685429 10789670 · DOI · Paper page
  20. [22]Moher D. Liberati A. Tetzlaff J. Altman D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement British Medical Journal 2009 339 b2535 10.1136/bmj.b2535 2-s2.0-69449100622 PMC3090117 21603045 · DOI · Paper page
  21. [23]Tierney J. F. Stewart L. A. Ghersi D. Burdett S. Sydes M. R. Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 8 1 p. 16 10.1186/1745-6215-8-16 2-s2.0-34547450763 PMC1920534 17555582 · DOI · Paper page
  22. [24]Altman D. G. Bland J. M. How to obtain the confidence interval from a P value British Medical Journal 2011 343 681 681 10.1136/bmj.d2090 2-s2.0-84858999738 · DOI
  23. [25]Andreas S. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses European Journal of Epidemiology 2010 25 9 603 605 10.1007/s10654-010-9491-z 2-s2.0-77957661914 20652370 · DOI · Paper page
  24. [26]Higgins J. P. T. Thompson S. G. Deeks J. J. Altman D. G. Measuring inconsistency in meta-analyses British Medical Journal 2003 327 7414 557 560 10.1136/bmj.327.7414.557 2-s2.0-0041876133 12958120 PMC192859 · DOI · Paper page
  25. [27]Lai N. Dong Q. Ding H. Miao Z. Lin Y. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients Journal of Clinical Neuroscience 2014 21 5 755 760 10.1016/j.jocn.2013.06.024 24382515 · DOI
  26. [28]Qiu S. Lin S. Hu D. Feng Y. Tan Y. Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients Journal of Translational Medicine 2013 11 10 10.1186/1479-5876-11-10 2-s2.0-84872050193 PMC3551827 23302469 · DOI
  27. [29]Zhi F. Chen X. Wang S. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma European Journal of Cancer 2010 46 9 1640 1649 10.1016/j.ejca.2010.02.003 2-s2.0-77952583615 20219352 · DOI
  28. [30]Srinivasan S. Patric I. R. P. Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma PLoS One 2011 6 3 e17438 10.1371/journal.pone.0017438 PMC3069027 21483847 · DOI
  29. [31]Zhao S. Yang G. Mu Y. MiR-106a is an independent prognostic marker in patients with glioblastoma Neuro-oncology 2013 15 6 707 717 10.1093/neuonc/not001 2-s2.0-84878268595 23416698 PMC3661090 · DOI
  30. [32]Men D. Liang Y. Chen L. Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients Cancer Epidemiology 2014 38 2 152 156 10.1016/j.canep.2014.01.003 2-s2.0-84898021452 24559637 · DOI
  31. [33]Liu Q. Tang H. Liu X. MiR-200b as a prognostic factor targets multiple members of RAB family in glioma Medical Oncology 2014 31 3 p. 859 10.1007/s12032-014-0859-x 2-s2.0-84892936699 24477653 · DOI
  32. [34]Chen W. Yu Q. Chen B. Lu X. Li Q. The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients Oncotarget 2016 7 33 53392 53413 10.18632/oncotarget.10534 27438144 PMC5288195 · DOI
  33. [35]Wang W. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis International Journal of Cancer Journal International Du Cancer 2012 130 7 1620 1628 10.1002/ijc.26177 2-s2.0-84856358368 21557218 · DOI
  34. [36]Zhang R. Pang B. Xin T. Plasma miR-221/222 family as novel descriptive and prognostic biomarkers for glioma Molecular Neurobiology 2016 53 3 1452 1460 10.1007/s12035-014-9079-9 25636684 · DOI
  35. [37]Guan Y. Mizoguchi M. Yoshimoto K. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance Clinical Cancer Research 2010 16 16 4289 4297 10.1158/1078-0432.CCR-10-0207 2-s2.0-77955719235 20601442 · DOI
  36. [38]Barbano R. Palumbo O. Pasculli B. A MiRNA signature for defining aggressive phenotype and prognosis in gliomas PLoS One 2014 9 10 e108950 10.1371/journal.pone.0108950 PMC4184816 25279461 · DOI
  37. [39]Lu S. Wang S. Geng S. Ma S. Liang Z. Jiao B. Increased expression of microRNA-17 predicts poor prognosis in human glioma Journal of Biomedicine and Biotechnology 2012 2012 6 970761 10.1155/2012/970761 PMC3514846 23226946 · DOI
  38. [40]Chen Y. Y. Hsu C. Y. Ho D. M. T. Upregulated MIR-125, MIR-181D and MIR-221 expression levels are associated with poor prognosis in glioblastoma patients with unmethylated mgmt promoter Laboratory Investigation 2017 97 428 440 10.1038/labinvest.2016.177 28134874 · DOI
  39. [41]Zhao H. Shen J. Hodges T. R. Song R. Fuller G. N. Heimberger A. B. Serum microRNA profiling in patients with glioblastoma: A survival analysis Molecular Cancer 2017 16 1 10.1186/s12943-017-0628-5 2-s2.0-85014916173 PMC5346242 28284220 · DOI
  40. [42]Sun J. Shi H. Lai N. Liao K. Zhang S. Lu X. Overexpression of microRNA-155 predicts poor prognosis in glioma patients Medical Oncology 2014 31 4, article no. 911 2-s2.0-84895778013 10.1007/s12032-014-0911-x 24623016 · DOI
  41. [43]Jiang L. Mao P. Song L. miR-182 as a prognostic marker for glioma progression and patient survival The American Journal of Pathology 2010 177 1 29 38 10.2353/ajpath.2010.090812 2-s2.0-77954579109 20472885 PMC2893648 · DOI
  42. [44]Hermansen S. K. Dahlrot R. H. Nielsen B. S. Hansen S. Kristensen B. W. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas Journal of Neuro-Oncology 2013 111 1 71 81 10.1007/s11060-012-0992-3 23104517 · DOI
  43. [45]Chen T. Wang X. Li C. Xu S. Downregulation of microRNA-124 predicts poor prognosis in glioma patients Neurological Sciences 2015 36 1 131 135 10.1007/s10072-014-1895-1 25112530 · DOI
  44. [46]Zhang X. Cheng J. Fu L. Li Q. Overexpression of tissue microRNA10b may help predict glioma prognosis Journal of Clinical Neuroscience 2016 29 59 63 10.1016/j.jocn.2015.10.046 26988656 · DOI
  45. [47]Xiao Y. Zhang L. Song Z. Potential diagnostic and prognostic value of plasma circulating microrna-182 in human glioma Medical Science Monitor 2016 22 855 862 10.12659/MSM.897164 2-s2.0-84962505912 26978735 PMC4795091 · DOI
  46. [48]Guan Y. Chen L. Bao Y. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma International Journal of Clinical and Experimental Pathology 2015 8 6 6576 6588 2-s2.0-84938569555 26261539 PMC4525873
  47. [49]Lai N. S. Wu D. G. Fang X. G. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma British Journal of Cancer 2015 112 7 1241 1246 10.1038/bjc.2015.91 25756397 PMC4385967 · DOI
  48. [50]Kim J. Zhang Y. Skalski M. microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma Cancer Research 2014 74 5 1541 1553 10.1158/0008-5472.CAN-13-1449 24425048 PMC3947487 · DOI
  49. [51]Lakomy R. Sana J. Hankeova S. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients Cancer Science 2011 102 12 2186 2190 2-s2.0-81855192731 10.1111/j.1349-7006.2011.02092.x 21895872 PMC11158343 · DOI
  50. [52]Xue L. Wang Y. Yue S. Zhang J. The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis Neurological Sciences 2017 38 1 67 73 10.1007/s10072-016-2710-y 27629767 · DOI
  51. [53]Sun G. Shi L. Yan S. MiR-15b targets cyclin D1 to regulate proliferation and apoptosis in glioma cells BioMed Research International 2014 2014 9 687826 10.1155/2014/687826 PMC4065679 24995320 · DOI
  52. [54]Chan J. A. Krichevsky A. M. Kosik K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Research 2005 65 14 6029 6033 10.1158/0008-5472.CAN-05-0137 2-s2.0-22244467087 16024602 · DOI · Paper page
  53. [55]Han L. Yue X. Zhou X. MicroRNA-21 expression is regulated by β-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK CNS Neuroscience & Therapeutics 2012 18 7 573 583 10.1111/j.1755-5949.2012.00344.x 22630347 PMC6493520 · DOI
  54. [56]Zheng X. Chopp M. Lu Y. Buller B. Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3 Cancer Letters 2013 329 2 146 154 10.1016/j.canlet.2012.10.026 23142217 PMC3553580 · DOI
  55. [57]Quintavalle C. Donnarumma E. Iaboni M. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells Oncogene 2013 32 34 4001 4008 10.1038/onc.2012.410 22964638 · DOI
  56. [58]Yang G. Han D. Chen X. MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IκBα both in vitro and in vivo Neuro-Oncology 2014 16 5 652 661 10.1093/neuonc/not307 24463357 PMC3984554 · DOI
  57. [59]Yekta S. Shih I.-H. Bartel D. P. MicroRNA-Directed Cleavage of HOXB8 mRNA Science 2004 304 5670 594 596 2-s2.0-2142654329 10.1126/science.1097434 15105502 · DOI · Paper page
  58. [60]Grier D. G. Thompson A. Kwasniewska A. McGonigle G. J. Halliday H. L. Lappin T. R. The pathophysiology of HOX genes and their role in cancer The Journal of Pathology 2005 205 2 154 171 2-s2.0-13644265950 10.1002/path.1710 15643670 · DOI
  59. [61]Abdel-Fattah R. Xiao A. Bomgardner D. Pease C.-S. Lopes M.-B. S. Hussaini I. M. Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes The Journal of Pathology 2006 209 1 15 24 2-s2.0-33645984886 10.1002/path.1939 16463268 · DOI
  60. [62]Alaiti M. A. Ishikawa M. Masuda H. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis Journal of Cellular and Molecular Medicine 2012 16 10 2413 2421 2-s2.0-84866770765 10.1111/j.1582-4934.2012.01557.x 22360314 PMC3823435 · DOI
  61. [63]Fasanaro P. Greco S. Lorenzi M. An integrated approach for experimental target identification of hypoxia-induced miR-210 The Journal of Biological Chemistry 2009 284 50 35134 35143 10.1074/jbc.m109.052779 2-s2.0-71749100911 19826008 PMC2787374 · DOI
  62. [64]Tsuchiya S. Fujiwara T. Sato F. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1) The Journal of Biological Chemistry 2011 286 1 420 428 2-s2.0-78650944900 10.1074/jbc.M110.170852 21044961 PMC3013001 · DOI
  63. [65]Zhang J. Han L. Ge Y. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway International Journal of Oncology 2010 36 4 913 920 2-s2.0-77749340705 10.3892/ijo-00000570 20198336 · DOI
  64. [66]Zhang Z. Li Z. Gao C. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression Laboratory Investigation 2008 88 12 1358 1366 10.1038/labinvest.2008.94 2-s2.0-56649120601 18794849 · DOI · Paper page
  65. [67]Furuta M. Kozaki K.-I. Tanaka S. Arii S. Imoto I. Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma Carcinogenesis 2009 31 5 766 776 2-s2.0-77952299722 10.1093/carcin/bgp250 19843643 · DOI
  66. [68]Medina R. Zaidi S. K. Liu C.-G. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival Cancer Research 2008 68 8 2773 2780 10.1158/0008-5472.can-07-6754 2-s2.0-42349093068 18413744 PMC3613850 · DOI
  67. [69]Ma L. Teruya-Feldstein J. Weinberg R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer Nature 2007 449 7163 682 688 2-s2.0-35148886434 10.1038/nature06174 17898713 · DOI · Paper page
  68. [70]Wei J. Wang F. Kong L.-Y. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma Cancer Research 2013 73 13 3913 3926 10.1158/0008-5472.can-12-4318 2-s2.0-84880062228 23636127 PMC3780786 · DOI
  69. [71]Molitoris J. K. McColl K. S. Distelhorst C. W. Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17-92 contributes to the induction of bim and initiation of apoptosis Molecular Endocrinology 2011 25 3 409 420 2-s2.0-79952165235 10.1210/me.2010-0402 21239610 PMC3045743 · DOI
  70. [72]Sasayama T. Nishihara M. Kondoh T. Hosoda K. Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC International Journal of Cancer 2009 125 6 1407 1413 2-s2.0-68249139817 10.1002/ijc.24522 19536818 · DOI
  71. [73]Alonso M. M. Fueyo J. Shay J. W. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance Journal of the National Cancer Institute 2005 97 21 1589 1600 10.1093/jnci/dji340 2-s2.0-27944476391 16264179 · DOI
  72. [74]Liu C. Tu Y. Sun X. Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations Clinical & Experimental Medicine 2011 11 2 105 112 10.1007/s10238-010-0110-9 20809334 · DOI
  73. [75]Sallinen S.-L. Sallinen P. K. Kononen J. T. Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis The Journal of Pathology 1999 188 3 289 293 2-s2.0-0033053058 10.1002/(SICI)1096-9896(199907)188:3<289::AID-PATH351>3.0.CO;2-X 10419598 · DOI · Paper page
  74. [76]Wang Z. Wang B. Shi Y. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2 Oncogene 2015 34 11 1407 1419 2-s2.0-84897356601 10.1038/onc.2014.75 24704830 · DOI
  75. [77]Yu J. Cai X. He J. Zhao W. Wang Q. Liu B. Microarray-based analysis of gene regulation by transcription factors and microRNAs in glioma Neurological Sciences 2013 34 8 1283 1289 10.1007/s10072-012-1228-1 23212403 · DOI
  76. [78]Ling N. Gu J. Lei Z. MicroRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma Oncology Reports 2013 30 5 2111 2118 2-s2.0-84885076418 10.3892/or.2013.2685 23970205 · DOI
  77. [79]Cobbs C. S. Whisenhunt T. R. Wesemann D. R. Harkins L. E. Van Meir E. G. Samanta M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells Cancer Research 2003 63 24 8670 8673 2-s2.0-0346690271 14695179
  78. [80]Segura M. F. Hanniford D. Menendez S. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor Proceedings of the National Acadamy of Sciences of the United States of America 2009 106 6 1814 1819 2-s2.0-60549112361 10.1073/pnas.0808263106 PMC2634798 19188590 · DOI
  79. [81]Xia H. Qi Y. Ng S. S. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs Brain Research 2009 1269 158 165 10.1016/j.brainres.2009.02.037 19265686 · DOI
  80. [82]Ji Y. Wei Y. Wang J. Gong K. Zhang Y. Zuo H. Correlation of microRNA-10b upregulation and poor prognosis in human gliomas Tumor Biology 2015 36 8 6249 6254 10.1007/s13277-015-3310-9 25773393 · DOI
  81. [83]Wei X. Chen D. Lv T. Li G. Qu S. Serum microRNA-125b as a potential biomarker for glioma diagnosis Molecular Neurobiology 2016 53 1 163 170 10.1007/s12035-014-8993-1 25416859 · DOI
  82. [84]He X. Liao Y. Guo X. Wang R. Xiao Z. Wang Y. Prognostic role of microRNA-21 expression in brain tumors: a meta-analysis Molecular Neurobiology 2016 53 3 1856 1861 10.1007/s12035-015-9140-3 25790954 · DOI
  83. [85]Wu J. Li L. Jiang C. Identification and evaluation of serum microRNA-29 family for glioma screening Molecular Neurobiology 2015 52 3 1540 1546 10.1007/s12035-014-8937-9 25367878 · DOI
  84. [86]Pfeffer S. R. Yang C. H. Pfeffer L. M. The Role of MIR-21 in Cancer Drug Development Research 2015 76 6 270 277 2-s2.0-84941259771 10.1002/ddr.21257 26082192 · DOI · Paper page
  85. [87]Ling M. Li Y. Xu Y. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-κB in arsenite-induced cell transformation Free Radical Biology & Medicine 2012 52 9 1508 1518 2-s2.0-84858959583 10.1016/j.freeradbiomed.2012.02.020 22387281 · DOI
  86. [88]Ciafrè S. A. Galardi S. Mangiola A. Extensive modulation of a set of microRNAs in primary glioblastoma Biochemical and Biophysical Research Communications 2005 334 4 1351 1358 10.1016/j.bbrc.2005.07.030 2-s2.0-23044464236 16039986 · DOI · Paper page
  87. [89]Huse J. T. Brennan C. Hambardzumyan D. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes & Development 2009 23 11 1327 1337 2-s2.0-66149173789 10.1101/gad.1777409 19487573 PMC2701585 · DOI
  88. [90]Rao S. A. M. Santosh V. Somasundaram K. Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma Modern Pathology 2010 23 10 1404 1417 2-s2.0-77957561251 10.1038/modpathol.2010.135 20711171 · DOI
  89. [91]Yang G. Zhang R. Chen X. MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status Journal of Molecular Medicine 2011 89 10 1037 1050 2-s2.0-80755140088 10.1007/s00109-011-0775-x 21656380 · DOI
  90. [92]Hunt S. Jones A. V. Hinsley E. E. Whawell S. A. Lambert D. W. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1 FEBS Letters 2011 585 1 187 192 2-s2.0-78650864750 10.1016/j.febslet.2010.11.038 21112327 · DOI
  91. [93]Wilting S. M. van Boerdonk R. A. A. Henken F. E. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer Molecular Cancer 2010 9 1 p. 167 10.1186/1476-4598-9-167 2-s2.0-77953853387 PMC2917428 20579385 · DOI
  92. [94]Shan S. W. Lee D. Y. Deng Z. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression Nature Cell Biology 2009 11 8 1031 1038 2-s2.0-68249126627 10.1038/ncb1917 19633662 · DOI
  93. [95]Chen X. Ba Y. Ma L. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases Cell Research 2008 18 10 997 1006 10.1038/cr.2008.282 2-s2.0-53349177819 18766170 · DOI · Paper page
  94. [96]Lu L. Mao X. Shi P. MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis Medicine 2017 96 22 e7085 10.1097/MD.0000000000007085 PMC5459744 28562579 · DOI
  95. [97]Hu G. Y. Tao F. Wang W. Ji K. W. Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis World Journal of Surgical Oncology 2016 14 82 10.1186/s12957-016-0842-4 PMC4786997 26969625 · DOI
  96. [98]Zhang Y. Guan D.-H. Bi R.-X. Xie J. Yang C.-H. Jiang Y.-H. Prognostic value of microRNAs in gastric cancer: A meta-analysis Oncotarget 2017 8 33 55489 55510 2-s2.0-85029051534 28903436 PMC5589675

Cited by

Sorted by citations

Authors
Zhang, Y., Chen, J., Xue, Q., Wang, J., Zhao, L., Han, K., Zhang, D., & Hou, L.
Affiliations
Second Military Medical University (CN)
Corresponding author
  • Zhao, Liang
  • Han, Kaiwei
  • Zhang, Danfeng
  • Hou, Lijun
ORCID
Venue
BioMed Research International
Publisher
Wiley
Published
2019-03-26
Volume
2019
Pages
1-14
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
DOI
10.1155/2019/4015969
PMC
PMC6457304
OpenAlex
W2925231458
Cited by
32
References
2
Citations by year
2025: 1 · 2024: 11 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 11 · 2019: 2
FWCI
0.46
Type
journal article
Language
en
Open access
Licence
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
microRNA, glioma, prognosis, prognostic factors, miR-15b, miR-21, miR-148a, miR-196, miR-210, miR-221, miR-106a, miR-124, survival, microRNA expression
MeSH terms
Glioma, Humans, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Analysis, Disease-Free Survival, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review